Trial Details
Not recruitingBasic Information
| Clinical ID | c2956 |
|---|---|
| Identifier | NCT02680756 |
| Trial Title | A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease |
| Trial URL | Visit Original Page |
Study Information
| Study Results | Yes |
|---|---|
| Conditions | Anemia, Iron-Deficiency;Inflammatory Bowel Disease;Crohn's Disease |
| Interventions | Drug: Ferric Maltol;Drug: Ferric Carboxy Maltose |
Participant Information
| Sponsor | Shield Therapeutics |
|---|---|
| City | - |
| Country/Region | United States;Belgium;France;Germany;Hungary;Spain |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | - |
Study Design
| Study Type | Interventional |
|---|---|
| Phase | PHASE3 |
Time Information
| Start Date | 2025-04-24 |
|---|---|
| Primary Completion Date | 2020-02-24 |
| Completion Date | - |